The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis

被引:10
作者
Zhang, Xiaoyun [1 ,2 ]
Song, Ying [1 ]
Wei, Zhiqiang [1 ]
Chen, Xiao [1 ]
Zhuang, Xiaojia [1 ]
Yi, Li [1 ]
机构
[1] Peking Univ, Neurol Dept, Shenzhen Hosp, Shenzhen, Peoples R China
[2] Shenzhen Longhua Dist Cent Hosp, Rehabil Dept, Shenzhen, Peoples R China
关键词
multiple sclerosis; anxiety; prevalence; risk factor; meta-analysis; QUALITY-OF-LIFE; MENTAL-HEALTH; DIAGNOSTIC-CRITERIA; DEPRESSION; GENDER; DISORDERS; REVISIONS; FATIGUE; MOOD;
D O I
10.3389/fnins.2023.1120541
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background Patients with multiple sclerosis (MS) suffer from repetitive neurological deterioration, while anxiety may play a significant role in the disease's progression.Objective To explore the prevalence of anxiety in MS and to investigate the risk factors related to anxiety in MS patients.Methods An analysis of four databases, PubMed, Web of Science, EMBASE, and Cochrane Library, has been conducted to determine the prevalence or risk factors for anxiety in MS published before May 2021.Results In total, 32 studies were found to be eligible. Anxiety prevalence was estimated to be 36% based on the pooled estimates [the 95% confidence interval (CI) = [0.30-0.42], I-2 = 98.4%]. Significant risk factors for developing of anxiety were as follows: age at survey [the weighted mean difference (WMD) = 0.96, 95% CI = [0.86-1.06], I-2 = 43.8%], female [the odd ratio (OR) = 1.78, 95% CI = [1.38-2.30], I-2 = 0%], living together (OR 2.83, 95% CI = [1.74-4.59], I-2 = 0%), past psychiatric history (OR 2.42, 95% CI = [1.56-3.75], I-2 = 0%), depression (OR 7.89, 95% CI = [3.71-16.81], I-2 = 0%), not taking MS medication (OR 2.33, 95% CI = [1.29-4.21], I-2 = 77.8%), relapsing-remitting MS (RRMS) (OR 1.50, 95% CI = [0.94-2.37], I-2 = 53.5%), and baseline Expanded Disability Status Scale (EDSS) (OR 0.84, 95% CI = [0.48-1.21], I-2 = 62.2%).Conclusion An estimated 36% of people with MS suffer from anxiety. And anxiety rates in MS patients are significantly associated with age, gender, living together, prior psychiatric history, depression, drug compliance, RRMS, and baseline EDSS.
引用
收藏
页数:16
相关论文
共 75 条
[1]   Pathogenic involvement of neuropeptides in anxiety and depression [J].
Alldredge, Brett .
NEUROPEPTIDES, 2010, 44 (03) :215-224
[2]   Sex differences in anxiety and depression clinical perspectives [J].
Altemus, Margaret ;
Sarvaiya, Nilofar ;
Epperson, C. Neill .
FRONTIERS IN NEUROENDOCRINOLOGY, 2014, 35 (03) :320-330
[3]  
Askari Fariba, 2014, Acta Med Iran, V52, P889
[4]   Systematic review of studies on quality of life indexed on the Scielo database [J].
Bastos Landeiro, Graziela Macedo ;
Raimundo Pedrozo, Celine Cristina ;
Gomes, Maria Jose ;
Oliveira, Elizabete Regina de Araujo .
CIENCIA & SAUDE COLETIVA, 2011, 16 (10) :4257-4266
[5]  
Beghi E, 2019, LANCET NEUROL, V18, P357, DOI [10.1016/S1474-4422(18)30454-X, 10.1016/S1474-4422(18)30443-5, 10.1016/S1474-4422(19)30034-1]
[6]  
Berkman N D., 2008, Methods Guide for Effectiveness and Comparative Effectiveness Reviews
[7]   Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis [J].
Bessing, Barnabas ;
Hussain, Mohammad A. ;
Claflin, Suzi B. ;
Chen, Jing ;
Blizzard, Leigh ;
van Dijk, Pieter ;
Kirk-Brown, Andrea ;
Taylor, Bruce, V ;
van der Mei, I .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (13) :2093-2102
[8]   Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis [J].
Boeschoten, Rosa E. ;
Braamse, Annemarie M. J. ;
Beekman, Aartjan T. F. ;
Cuijpers, Pim ;
van Oppen, Patricia ;
Dekker, Joost ;
Uitdehaag, Bernard M. J. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 372 :331-341
[9]   Do anxiety and depression have a common pathophysiological mechanism? [J].
Boyer, P .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 :24-29
[10]   Diagnosis and measurement of anxiety disorder in adolescents: A review of commonly used instruments [J].
Brooks, SJ ;
Kutcher, S .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (03) :351-400